VivoSeq
Other

Tolerance

0

Pipeline Programs↗

10

Active Trials↗

34

Companies Involved↗

Tolerance is an early-stage landscape with 0 programs across 34 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Boehringer Ingelheim, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalT

Talaris Therapeutics Inc.

0 programs

PreclinicalInnovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

0 programs

PreclinicalGilead logo

Gilead

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

183

clinical trials

Completed118 · 64%
Unknown status38 · 21%
Terminated14 · 8%
Recruiting5 · 3%
Active, not recruiting3 · 2%
Not yet recruiting2 · 1%
Other3 · 2%

Clinical Trials

Trial Activity

183 trials

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Recruiting·—·Phase 4·NCT05051436·96 enrolled
Effect OF Lactase Enzyme Supplements ON Intolerance IN Preterm Neonates
Recruiting·—·N/A·NCT07088302·120 enrolled
Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers
Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 1·NCT06024421·39 enrolled
Tolerance Through Mixed Chimerism (Sip-Tego)
Recruiting·TTatsuo Kawai, MD, PhD·Phase 1·NCT06972069·12 enrolled
Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) Trial
Recruiting·MMorehouse School of Medicine·Phase 4·NCT07215000·300 enrolled
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
Active, not recruiting·MMassachusetts General Hospital·Phase 1·NCT04540380·20 enrolled
Induction of Transplant Tolerance in LDLT Via iTS
Active, not recruiting·JJuntendo University·Phase 1/2·NCT04950842·10 enrolled
Delayed Tolerance Through Mixed Chimerism
Active, not recruiting·MMassachusetts General Hospital·Phase 1/2·NCT05900401·20 enrolled
Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance
Not yet recruiting·JJohns Hopkins University·Phase 1·NCT06351540·40 enrolled
Exploring The Effect Of Cannabidiol On Cannabis Tolerance Using A Novel Vaporiser Device In Heavy Users (Stage 1)
Not yet recruiting·KKing's College London·N/A·NCT07471347·10 enrolled
Effect of Medicago Sativa on Oral Glucose Tolerance in Healthy Adults
Completed·UUniversity of Guadalajara·Phase 2·NCT03714438·15 enrolled
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#
Completed·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT05270928·6 enrolled
Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001133·50 enrolled
Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT02268760·103 enrolled
Comparative Study on Tolerance and Pharmacokinetics of Voriconazole for Injection in Healthy Subjects
Completed·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT05330000·48 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)